Mithridion, Inc

Description

Mithridion focuses on the development of drugs for unmet clinical needs in serious Central Nervous System (CNS) disorders, including Alzheimer’s disease (AD) and schizophrenia. In February 2006, Mithridion raised its first equity funding from angel investors, enabling it to commence operations, and to build a strong CNS drug research and development team.

Companies nearby